The rapid evolution of treatment for advanced lung cancer is a story of how scientists have
struggled to move from nonselective cytotoxic chemotherapy to personalized precision …

Lung, breast, and esophageal cancer represent three common malignancies with high
incidence and mortality worldwide. The management of these tumors critically relies on …

Background Ensartinib is a potent new-generation ALK inhibitor with high activity against a
broad range of known crizotinib-resistant ALK mutations and CNS metastases. We aimed to …

RET alterations have been characterized as oncogenic drivers in multiple cancers. The
clinical validation of highly selective RET inhibitors demonstrates the utility of specific …

Objectives There is an expanding list of therapeutically relevant biomarkers for non-small
cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition …

Lung carcinoma is one of the most common human cancers and is estimated to have an
incidence of approximately 2 million new cases per year worldwide with a 20% mortality …

Background The prognostic significance of TP53 concurrent mutations in patients with
epidermal growth factor receptor (EGFR)-or anaplastic lymphoma kinase (ALK)-mutated …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

Lung cancer is an extremely heterogeneous disease, and its treatment remains one of the
most challenging tasks in medicine. Few existing laboratory lung cancer models can …